Literature DB >> 31594858

Relationships between DMD mutations and neurodevelopment in dystrophinopathy.

Mathula Thangarajh1, Jos Hendriksen2, Michael P McDermott2, William Martens2, Kimberly A Hart2, Robert C Griggs2.   

Abstract

OBJECTIVE: We performed a prospective, cross-sectional analysis of neurodevelopmental concerns and psychosocial adjustment in relation to DMD mutations in young steroid-naive boys with dystrophinopathy.
METHODS: We evaluated 196 steroid-naive boys with dystrophinopathy who were enrolled in the Finding the Optimal Regimen for Duchenne Muscular Dystrophy trial. The neurodevelopmental concerns and psychosocial adjustment challenges were analyzed in relation to DMD mutation. A parent or legal guardian reported neurodevelopmental concerns in 4 domains (speech, learning and attentional difficulties, and autism spectrum disorder [ASD]) and completed the Personal Adjustment and Role Skills Scale to assess psychosocial adjustment. We also assessed whether boys of DMD carrier mothers were more vulnerable to speech delay and learning difficulties.
RESULTS: We found that 39% of boys were reported to have speech delay with a mean age of speaking at 28 months (range 7-66 months). Learning difficulties were reported in 28% of participants. Inattentive-overactive and oppositional-defiant behavior was reported in 8% and 5% of participants, respectively. Psychosocial adjustment challenges were reported in 4% of participants. An ASD diagnosis was reported in 3 participants. Speech delay and learning difficulties were more common in boys with mutations downstream of DMD exon 45. Neurodevelopmental concerns were not associated with DMD deletion, duplication, or point mutation subtype. Boys of DMD carrier mothers did not have longer speech delay or more learning difficulties.
CONCLUSION: Our data support evidence for a relationship between neurodevelopmental concerns and DMD mutation. A longitudinal assessment of developmental trajectory is necessary to evaluate how specific DMD mutations affect brain function.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31594858      PMCID: PMC6946466          DOI: 10.1212/WNL.0000000000008363

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  47 in total

1.  Assessing psychosocial adjustment of children with chronic illnesses: a review of the technical properties of PARS III.

Authors:  D K Walker; R E Stein; E C Perrin; D J Jessop
Journal:  J Dev Behav Pediatr       Date:  1990-06       Impact factor: 2.225

2.  Autism spectrum disorders are prevalent among patients with dystrophinopathies.

Authors:  Haruo Fujino; Toshio Saito; Tsuyoshi Matsumura; Saki Shibata; Yuko Iwata; Harutoshi Fujimura; Osamu Imura
Journal:  Neurol Sci       Date:  2018-03-28       Impact factor: 3.307

3.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

4.  Reduced cerebral gray matter and altered white matter in boys with Duchenne muscular dystrophy.

Authors:  Nathalie Doorenweerd; Chiara S Straathof; Eve M Dumas; Pietro Spitali; Ieke B Ginjaar; Beatrijs H Wokke; Debby G Schrans; Janneke C van den Bergen; Erik W van Zwet; Andrew Webb; Mark A van Buchem; Jan J Verschuuren; Jos G Hendriksen; Erik H Niks; Hermien E Kan
Journal:  Ann Neurol       Date:  2014-07-24       Impact factor: 10.422

5.  Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.

Authors:  Michela Guglieri; Kate Bushby; Michael P McDermott; Kimberly A Hart; Rabi Tawil; William B Martens; Barbara E Herr; Elaine McColl; Jennifer Wilkinson; Janbernd Kirschner; Wendy M King; Michele Eagle; Mary W Brown; Tracey Willis; Deborah Hirtz; Perry B Shieh; Volker Straub; Anne-Marie Childs; Emma Ciafaloni; Russell J Butterfield; Iain Horrocks; Stefan Spinty; Kevin M Flanigan; Nancy L Kuntz; Giovanni Baranello; Helen Roper; Leslie Morrison; Jean K Mah; Adnan Y Manzur; Craig M McDonald; Ulrike Schara; Maja von der Hagen; Richard J Barohn; Craig Campbell; Basil T Darras; Richard S Finkel; Giuseppe Vita; Imelda Hughes; Tiziana Mongini; Elena Pegoraro; Matthew Wicklund; Ekkehard Wilichowski; W Bryan Burnette; James F Howard; Hugh J McMillan; Mathula Thangarajh; Robert C Griggs
Journal:  Contemp Clin Trials       Date:  2017-04-24       Impact factor: 2.226

6.  Deletion status and intellectual impairment in Duchenne muscular dystrophy.

Authors:  K M Bushby; R Appleton; L V Anderson; J L Welch; P Kelly; D Gardner-Medwin
Journal:  Dev Med Child Neurol       Date:  1995-03       Impact factor: 5.449

7.  Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations.

Authors:  Valeria Ricotti; William P L Mandy; Mariacristina Scoto; Marika Pane; Nicolas Deconinck; Sonia Messina; Eugenio Mercuri; David H Skuse; Francesco Muntoni
Journal:  Dev Med Child Neurol       Date:  2015-09-14       Impact factor: 5.449

8.  Psychosocial adjustment in males with Duchenne muscular dystrophy: psychometric properties and clinical utility of a parent-report questionnaire.

Authors:  Jos G M Hendriksen; James T Poysky; Debby G M Schrans; Eric G W Schouten; Albert P Aldenkamp; Johan S H Vles
Journal:  J Pediatr Psychol       Date:  2008-07-22

9.  Neurobehavioral characteristics of children with Duchenne muscular dystrophy.

Authors:  Jacobus Donders; Chand Taneja
Journal:  Child Neuropsychol       Date:  2009-01-22       Impact factor: 2.500

10.  Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy.

Authors:  Nathalie Doorenweerd; Ahmed Mahfouz; Maaike van Putten; Rajaram Kaliyaperumal; Peter A C T' Hoen; Jos G M Hendriksen; Annemieke M Aartsma-Rus; Jan J G M Verschuuren; Erik H Niks; Marcel J T Reinders; Hermien E Kan; Boudewijn P F Lelieveldt
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379

View more
  10 in total

1.  Single-transcript multiplex in situ hybridisation reveals unique patterns of dystrophin isoform expression in the developing mammalian embryo.

Authors:  John C W Hildyard; Abbe H Crawford; Faye Rawson; Dominique O Riddell; Rachel C M Harron; Richard J Piercy
Journal:  Wellcome Open Res       Date:  2020-07-20

2.  Clinical and Genetic Characteristics in Young, Glucocorticoid-Naive Boys With Duchenne Muscular Dystrophy.

Authors:  Marianela Schiava; Rachel Amos; Henriette VanRuiten; Michael P McDermott; Williams B Martens; Stephanie Gregory; Anna Mayhew; Elaine McColl; Rabi Tawil; Tracey Willis; Kate Bushby; Robert C Griggs; Michela Guglieri
Journal:  Neurology       Date:  2021-12-02       Impact factor: 9.910

Review 3.  Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy.

Authors:  Kay Ohlendieck; Dieter Swandulla
Journal:  Pflugers Arch       Date:  2021-09-22       Impact factor: 4.458

Review 4.  The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review.

Authors:  Shelagh M Szabo; Renna M Salhany; Alison Deighton; Meagan Harwood; Jean Mah; Katherine L Gooch
Journal:  Orphanet J Rare Dis       Date:  2021-05-22       Impact factor: 4.123

5.  Sex differences in the functional topography of association networks in youth.

Authors:  Sheila Shanmugan; Jakob Seidlitz; Zaixu Cui; Azeez Adebimpe; Danielle S Bassett; Maxwell A Bertolero; Christos Davatzikos; Damien A Fair; Raquel E Gur; Ruben C Gur; Bart Larsen; Hongming Li; Adam Pines; Armin Raznahan; David R Roalf; Russell T Shinohara; Jacob Vogel; Daniel H Wolf; Yong Fan; Aaron Alexander-Bloch; Theodore D Satterthwaite
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-08       Impact factor: 12.779

6.  Cognitive and behavioral functioning in two neurogenetic disorders; how different are these aspects in Duchenne muscular dystrophy and Neurofibromatosis type 1?

Authors:  Danique M J Hellebrekers; Sandra A M van Abeelen; Coriene E Catsman; Sander M J van Kuijk; Annick M Laridon; Sylvia Klinkenberg; Jos G M Hendriksen; Johan S H Vles
Journal:  PLoS One       Date:  2022-10-10       Impact factor: 3.752

7.  Longitudinal motor function in proximal versus distal DMD pathogenic variants.

Authors:  Mathula Thangarajh; Luca Bello; Heather Gordish-Dressman
Journal:  Muscle Nerve       Date:  2021-07-23       Impact factor: 3.217

Review 8.  Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy.

Authors:  Michael Naidoo; Karen Anthony
Journal:  Mol Neurobiol       Date:  2019-12-13       Impact factor: 5.590

9.  Transcriptional signatures of synaptic vesicle genes define myotonic dystrophy type I neurodegeneration.

Authors:  Antonio Jimenez-Marin; Ibai Diez; Garazi Labayru; Andone Sistiaga; Maria C Caballero; Pol Andres-Benito; Jorge Sepulcre; Isidro Ferrer; Adolfo Lopez de Munain; Jesus M Cortes
Journal:  Neuropathol Appl Neurobiol       Date:  2021-05-17       Impact factor: 6.250

10.  Duchenne Muscular Dystrophy Successfully Treated with Aripiprazole in a Patient with Autism Spectrum Disorder Symptoms Including Irritability.

Authors:  Seiya Noda; Ayuka Murakami; Seigo Kimura; Makoto Minamiyama; Masahisa Katsuno; Satoshi Kuru
Journal:  Intern Med       Date:  2021-06-19       Impact factor: 1.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.